Vimarsana
Biggest News Aggregation in the World

Page 4 - Mark Gergen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Gergen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Gergen Today - Breaking & Trending Today

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 - Vimarsana News

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022

Published: August 11, 2022

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform...

Source: prnewswire.com
Related Topics:
Georgem ChurchMark GergenCharlesm BaumHead Of ResearchCompany Board Of DirectorsDc ProgramPoseida Therapeutics IncExchange CommissionDevelopment ExpensesBoard Of Directors At Mirati Therapeutics IncProgram UpdatesBusiness DevelopmentPoseida TherapeuticsChief Executive OfficerTherapy CollaborationHart Scott Rodino Antitrust Improvements ActBoard Leadership UpdatesChair PoseidaGene Therapy Scientific AdvisoryMirati Therapeutics IncSecond QuarterSite Specific Gene Editing SystemPrivate Securities Litigation Reform ActMonths Ended June
Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies - Vimarsana News

Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies

Published: August 3, 2022

Leveraging Poseida's novel approach to cell therapy and Roche's expertise in developing and commercializing therapies to transform cancer care, the...

Source: prnewswire.com
Related Topics:
Mark GergenJames SabryDevonj ShedlockPoseida Therapeutics IncPrnewswire Poseida Therapeutics IncLeveraging PoseidaChief Executive OfficerGlobal HeadPharma PartneringChief Scientific OfficerCell TherapyHart Scott Rodino Antitrust Improvements ActTherapeutics Conference CallMedia SectionPoseida TherapeuticsSite Specific Gene Editing System
Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors - Vimarsana News

Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors

Published: May 19, 2022

Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors - read this article along with other careers information, tips and advice on BioSpace

Source: biospace.com
Related Topics:
United StatesMark GergenDavid HirschCharlesm BaumHead Of ResearchHead Of Oncology DevelopmentPoseida Therapeutics IncPrnewswire Poseida Therapeutics IncBioinnovation CenterAmerican Cancer SocietyNational Institutes Of HealthAcquisition CorpWashington University School Of MedicineExchange CommissionPfizer Worldwide Research DevelopmentBoard Of Directors At Mirati Therapeutics IncStanford UniversityBiotherapeutic Clinical ResearchChief Executive OfficerMirati Therapeutics IncSenior Vice PresidentWorldwide ResearchVice PresidentOncology DevelopmentChief Medical Officer
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021 - Vimarsana News

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021

Published: March 10, 2022

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform...

Source: prnewswire.com
Related Topics:
United StatesMark GergenEric OstertagKerry IngallsTakeda Pharmaceuticals United States IncDc ProgramPoseida Therapeutics IncPrnewswire Poseida Therapeutics IncExchange CommissionDevelopment ExpensesAmerican Society Of HematologyCompany TakedaOxford FinanceChief Executive OfficerAnnual MeetingClinical Oncology Genitourinary Cancers SymposiumTakeda Pharmaceuticals United StatesEmerging TechnologiesChief Operating OfficerChief Business OfficerExecutive ChairmanBrent WarnerGene TherapyFourth QuarterFull Year
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021 - Vimarsana News

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021

Published: March 10, 2022

SAN DIEGO, March 10, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing propriet...

Source: businessinsider.com
Related Topics:
United StatesMark GergenEric OstertagKerry IngallsTakeda Pharmaceuticals United States IncDc ProgramPoseida Therapeutics IncPrnewswire Poseida Therapeutics IncExchange CommissionAmerican Society Of HematologyDevelopment ExpensesCompany TakedaOxford FinanceChief Executive OfficerAnnual MeetingClinical Oncology Genitourinary Cancers SymposiumTakeda Pharmaceuticals United StatesEmerging TechnologiesChief Operating OfficerChief Business OfficerExecutive ChairmanBrent WarnerGene TherapyFourth QuarterFull Year